Mirada Medical USA Inc

(303) 379-9228http://www.mirada-medical.com

Request Information

Mirada Medical signs research collaboration agreement with reflexion medical to further development of biologically-guided radiation therapy

Multi-modality cancer imaging specialists Mirada Medical (Oxford UK) have teamed up with an emerging developer of radiation therapy equipment for fighting cancer, RefleXion Medical (Burlingame, CA), to evaluate the performance of RefleXion’s novel PET-guided radiotherapy system.

Oxford UK and Burlingame, CA, July 17, 2014: The relationship will contribute to important feasibility studies and proof-of-principle simulations that explore the potential of RefleXion’s system with clinical PET and CT imaging datasets.  
 
RefleXion Medical uniquely combines external beam radiation therapy with positron emission tomography (PET) imaging to deliver targeted radiation to one or multiple targets. Mirada Medical pioneered software for PET analysis in the early 2000’s and has been at the forefront of the movement to integrate PET imaging into radiation therapy planning. In working together, the companies expect to take the best of their respective technologies to deliver truly differential treatment modalities for cancer patients worldwide.
 
An initial study demonstrating the compatibility of RefleXion’s novel approach and state-of-the-art image registration techniques, using Mirada RTx, was recently completed and will be presented at AAPM 2014 in Austin, TX, during the ‘Joint Imaging – Therapy Scientific Session, Treatment Response Assessment’ on Thursday, July 24th.
 
Hugh Bettesworth, CEO of Mirada Medical said “Mirada has a very strong track record working with both PET imaging, and imaging for radiation treatment planning.  I am very excited to have this opportunity to partner with RefleXion and help establish a truly innovative approach to cancer radiotherapy”.
 
Sam Mazin, President of RefleXion Medical said “We are committed to working closely with industry leaders such as Mirada Medical in building upon established multi-modality image registration technologies and to transition the field towards truly adaptive radiation therapy”.  
 
 
For more information, please contact:
 
Mirada Medical
US/Worldwide: Robert Ripley                                                                            
tel: (440) 591-8638
Insource Communications
rripley@insourceinc.com
enquiries@mirada-medical.com
www.mirada-medical.com
 
U.S. Headquarters:
Mirada Medical USA, Inc.
999 18th Street
Suite 2025N
Denver, CO 80202
Tel: (303) 379-9228
 
World Headquarters:
Oxford Centre for Innovation
New Road, Oxford
OX1 1BY
United Kingdom
Tel: 44(0)1865 261410
 
About Mirada Medical Ltd
 
Mirada Medical is a leading international brand in medical imaging. The company develops advanced software applications which help healthcare professionals use medical images more effectively and efficiently to improve cancer care. Mirada’s products are used across diagnostic radiology, molecular imaging, radiation oncology, medical oncology, tumor board and elsewhere.
 
The company specializes in simplifying technically complex image processing tasks, allowing clinicians to more confidently diagnose disease, assess response to treatment and plan radiation therapy or surgical intervention. Mirada’s advanced software products are available throughout the world under its own brand, and on an OEM basis through a select number of the world’s leading healthcare companies.
 
Mirada Medical was originally spun out of the University of Oxford. The company’s technologies and products continue to be developed by their team of specialists, engineers and world-renowned scientists at Mirada’s world headquarters in Oxford, England.
 
Mirada Medical, RTx, Casemeeting, Caseaccess and XD3 are all trademarks of Mirada Medical Ltd.
 
About RefleXion Medical:
 
RefleXion Medical is a privately held medical device company developing the first biologically-guided radiation therapy system for cancer treatment. By leveraging Positron Emission Tomography (PET) in a novel way, RefleXion's patented technology will allow tumors to continuously signal their location during treatment and potentially revolutionize the practice of radiation oncology. Early validation of RefleXion's technology was funded by the National Cancer Institute at the National Institutes of Health, part of the U.S. Department of Health and Human Services (1R43CA153466-1A1). RefleXion is backed by premier venture capital firms Sofinnova Partners, Pfizer Venture Investments and Venrock. For more information, visit www.reflexionmedical.com and follow @reflexionmed on Twitter.

What’s new

Search all our content